Roxadustat: Ph III FGCL-4592-808 data

Top-line data from the double-blind, Chinese Phase III FGCL-4592-808 trial in 151 non-dialysis-dependent CKD patients with anemia showed that thrice-weekly oral roxadustat met the primary endpoint of increasing

Read the full 285 word article

User Sign In